Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

News Releases

  •   Email
  •   Print
  •   Share

  • In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs – designed to halt cancer cell division – do not just stop tumors from growing but can cause them to shrink, in some cases markedly.

Tags: BreastCancer, Immunotherapy

  • Scientists say they have validated a "surrogate endpoint" – a reliable statistical shortcut in a clinical trial – that could accelerate testing of new adjuvant therapies aimed at reducing deaths from prostate cancer in patients who were treated for localized disease, but are at risk of relapse.

Tags: ProstateCancer

  • Dana-Farber/Brigham and Women's Cancer Center has been ranked the highest for cancer care in New England for the 17th straight year, and fourth overall in the country by U.S. News & World Report.

Tags: Honors

  • Dana-Farber Cancer Institute is pleased to announce the opening of the new Leonard P. Zakim Center for Integrative Therapies and Healthy Living, underscoring Dana-Farber’s commitment to providing cutting-edge patient therapies and support for the “whole person” during and after treatment. Increasing data

  • In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes upon which cancer cells from multiple types are strongly dependent for their growth and survival.

  • A novel screening method developed by a team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center — using CRISPR

Tags: BasicResearch, Immunotherapy

  • The Kraft Family Blood Donor Center, which provides life-saving platelets and blood products to patients at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, is in urgent need of blood and platelet donors.

Tags: KraftCenter, BloodDonation

  • A personal cancer treatment vaccine that targets distinctive "neoantigens" on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Tags: BasicResearch, Melanoma

  • U.S. News & World Report has ranked Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #2 pediatric cancer program in its new 2017-18 Best Children's Hospitals report. This marks the ninth year since 2008 that Dana-Farber/Boston Children's has been ranked one of the top two pediatric cancer centers in the country.

Tags: ChildhoodCancer, Honors

  • Some patients with a form of advanced kidney cancer benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by Dana-Farber scientists.

Tags: chemotherapy, BasicResearch

Showing 1-10 of 797 items